Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy.

Luderer MJ, Muz B, Alhallak K, Sun J, Wasden K, Guenthner N, de la Puente P, Federico C, Azab AK.

Pharm Res. 2019 Aug 7;36(10):144. doi: 10.1007/s11095-019-2670-z.

PMID:
31392417
2.

Circulating microRNAs and Their Role in Multiple Myeloma.

Federico C, Sacco A, Belotti A, Ribolla R, Cancelli V, Giacomini A, Ronca R, Chiarini M, Imberti L, Marini M, Rossi G, Presta M, Paiva B, Roccaro AM.

Noncoding RNA. 2019 May 2;5(2). pii: E37. doi: 10.3390/ncrna5020037. Review.

3.

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma.

Amodio N, Gallo Cantafio ME, Botta C, Agosti V, Federico C, Caracciolo D, Ronchetti D, Rossi M, Driessen C, Neri A, Tagliaferri P, Tassone P.

Cancers (Basel). 2019 Feb 18;11(2). pii: E236. doi: 10.3390/cancers11020236.

4.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, GullĂ  A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P.

Blood. 2018 Sep 6;132(10):1050-1063. doi: 10.1182/blood-2018-03-836601. Epub 2018 Jul 11.

5.

Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.

de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK.

J Control Release. 2018 Jan 28;270:158-176. doi: 10.1016/j.jconrel.2017.11.045. Epub 2017 Nov 28.

6.

Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.

Muz B, Kusdono HD, Azab F, de la Puente P, Federico C, Fiala M, Vij R, Salama NN, Azab AK.

Leuk Lymphoma. 2017 Dec;58(12):2916-2925. doi: 10.1080/10428194.2017.1319052. Epub 2017 May 16.

7.

Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma.

Cosco D, Cilurzo F, Maiuolo J, Federico C, Di Martino MT, Cristiano MC, Tassone P, Fresta M, Paolino D.

Sci Rep. 2015 Dec 1;5:17579. doi: 10.1038/srep17579.

8.

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.

Pitari MR, Rossi M, Amodio N, Botta C, Morelli E, Federico C, GullĂ  A, Caracciolo D, Di Martino MT, Arbitrio M, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2015 Sep 29;6(29):27343-58. doi: 10.18632/oncotarget.4398.

9.

Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes.

Cosco D, Federico C, Maiuolo J, Bulotta S, Molinaro R, Paolino D, Tassone P, Fresta M.

Int J Nanomedicine. 2014 May 15;9:2359-72. doi: 10.2147/IJN.S58362. eCollection 2014.

10.

Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors.

Molinaro R, Wolfram J, Federico C, Cilurzo F, Di Marzio L, Ventura CA, Carafa M, Celia C, Fresta M.

Expert Opin Drug Deliv. 2013 Dec;10(12):1653-68. doi: 10.1517/17425247.2013.840286. Epub 2013 Oct 4. Review.

PMID:
24090239
11.

Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives.

Federico C, Morittu VM, Britti D, Trapasso E, Cosco D.

Int J Nanomedicine. 2012;7:5423-36. doi: 10.2147/IJN.S34025. Epub 2012 Nov 1. Review.

Supplemental Content

Loading ...
Support Center